

**REMARKS**

Currently claims **1 through 48** are pending. Claims 3, 5, 6, 9, 11, 13, 14, 15, 16, 20, 21, 23, 24, 25, 27, 29, 32, 33, 35, 36, 39, 42, 43 and 46 have been amended to reduce the filing fee by removing multiple dependencies and/or to correct typographical errors.


The specification has been amended to include a reference to related applications/claim of priority to the corresponding PCT application and foreign filed application.

Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Applicants respectfully submit that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance forthwith.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted:



Frank P. Grassler  
Attorney for Applicants  
Reg. No. 31,164

Date: July 28, 2006  
GlaxoSmithKline Inc.  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Tel. (919) 483-9024  
Fax: (919) 483-7988